INDEX

acute heart failure (AHF) (continued)
rapid triage and initial stabilization, 174–5
syndrome, 179
acute inflammation of the pericardium, 233
acute mitral regurgitation (MR), 203
acute myocardial infarction (AMI)
complications of, 51
criteria for, 332
defined by WHO, 331
EKG changes, 331–2
acute pericarditis/inflammation of pericardium, 230
acute tamponade, 232
adrenoreceptor activity, 178
advanced cardiac life support (ACLS) strategies, 131
guidelines, 76
advanced life support treatment (ALS) protocols, 130
AFFIRM trial, 93
akinesis, 64
alcoholic cardiomyopathy, 245
alcohol-induced dysrhythmia, 244
alpha-2-agonists, 79
American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, 7, 48, 350
2004 guidelines, 367
American College of Cardiology and European Society of Cardiology, 12
American College of Emergency Physicians, 11
American-European Atrial Fibrillation guidelines, 90
American Heart Association (AHA), 63, 124, 130, 133, 139, 140
2005 guidelines, 132
amiodarone, 364
amphetamine abuse and cardiovascular diseases, 246–7
angiotensin-converting enzyme inhibitors (ACE) inhibitors, 261, 298
antibiotic regimen, for patient with endocarditis, 206–7
anticoagulant drugs, 49
anticoagulant therapy, 48
anticoagulation, 90
antidysrhythmics, 131–2
agents, 154
cause of prolonged QT-related dysrhythmias, 249
drugs, 125, 367
anti-platelet therapy, 29, 111
antithrombotic therapy, 29
anxiety, 192
aortic dissection, 269
case discussion, 269–74
case presentation, 269
case resolution, 274
clinical factors, 275
Debakey and Stanford classification schemes, 275
decision making, 281
differential diagnosis, 275
EKG, 276
emergency department diagnosis, 279–80
emergency treatment, 280
epidemiology, 274–6
history, 276
imaging studies, 277–9
chest CT image, 279
multidetector CT (MDCT) coronary angiography, 279
transesophageal echocardiogram, 278
laboratory studies, 276
pathophysiology, 274–6
physical examination, 276
prognosis for patients, 281
promising marker for, 277
surgical treatment, 280–1
aortic stenosis (AS), 186, 192, 202
apical ballooning syndrome, 58, 63
aspirin, 40, 234, 367
affects of, 6
atherosclerotic coronary artery disease (ASCAD), 60, 62
associated ischemia, 63
risk factors for, 60
atrial fibrillation, 86–94, 380
acute management, 92–4
background, 89–90
case discussion, 86–9
case presentation, 86
case resolution, 89
decision making, 94
disposition, 94
initial atrial fibrillation workup, 90
rate control medications for, 93
testing, 91–2
atrial natriuretic factor, 102
atrioventricular (AV) block degrees, 88
conduction, 155
junctional rhythm, 79, 80
nodal, 49
nodal reentry (AVRT), 98
antidromic, 105
orthodromic, 105
orthodromic, reentry mechanism for, 104
nodal reentry tachycardia, 100
node, 73, 101, 154
pacing, 147
synchrony, 155
atropine, 76
auscultation, 203
automatic external defibrillators (AED), 139, 140
efficacy of, 145
home placement, 140
use of, 142
automatic implantable cardioverter defibrillator
(AICD), 150
AV reentry tachycardia (AVNRT), 98, 103
A-waves, 153
bacteremia, 202, 204
basic life support (BLS), 124
battery depletion, 153
Behçet’s syndrome, 78
beta-adrenergic blockers, in drug-induced heart disease,
250–1
beta-adrenergic receptors
concentrations, 63
beta-agonists, 99
beta-blockers, 6, 28, 41, 73, 100, 293, 355, 364
benefits of, 28
do/sex, 23
therapy, 28
toxicity, 133
use, 23
bicuspid aortic valve, 202
biomarkers, 21, 349, 352
blood pressures, 148, 186, 190
drops, 76
on infant, 372
blurred vision, 191
BNP levels, 156
Boerhaave’s syndrome, 9
bradycardia, 150
definition, 76
extrinsic causes of, 78, 79
bradydysrhythmias, 49, 71–84, 150
background/epidemiology, 76–7
case presentation, 71–6
case resolution, 76
common symptoms of, 72
decision making, 84
disposition, 83–4
etiologies/differential diagnosis, 77–9
initial workup history and physical, 77
management of, 83
pharmacologic doses in, 84
testing, 79–83
bradydysrhythmia, 77
British Pacing and Electrophysiology Group (BPEG), 152
broadly-defined syndrome, 78
“broken heart” syndrome, 63
Bruce protocol, 21
bypass graft surgical techniques, 125
calcium channel blockers, 84, 91, 97, 100, 133
blocking agents, 106
in drug-induced heart disease, 251
calcium chloride, 126
calcium sensitizer, 178
cancer-related pericarditis, 233
cannon, 153
capnography, 129
carbon monoxide (CO), 61
poisoning, historical clues for, 62
carboxyhemoglobin (CoHb), 61
cardiac arrest, 123–35
advanced life support and emergency care for, 131
antidysrhythmics, 131–2
background, 128
basic life support (BLS), 130–1
case discussion, 123–8
case presentation, 123
case resolution, 127–8
decision making, 134–5
epidemiology, 128
future directions in care, 134
initial patient assessment, 128–30
out-of-hospital cardiac arrest (OOGCA), 130–1
post-cardiac arrest ED care, 133–4
protocol, out-of-hospital termination, 135
specific clinical situations, 132–3
vasopressors, 132
cardiac auscultation, 153, 202
cardiac biomarkers, 46
cardiac catheterization, 56, 58, 63, 64
laboratory, 47
cardiac computed tomography (CCT) angiography,
354–5
advantages, 358
sensitivity of, 356
utility, 356
cardiac dysrhythmia, 186
cardiac echocardiogram, 56
cardiac emergency, 87
cardiac examination, 147
cardiac infarction
treatment for, 60
cardiac ischemia, 305, 311
nonatherosclerotic, cause of, 59
treatment of, 62
cardiac markers, 4, 12, 326
  cardiac troponins, 332–4
  case discussion, 327–31
  case presentation, 326–7
  case resolution, 331
  CK-MB, 332
  creatine kinase, 332, 334
  decision making, 335
  relative risk and, 334
  cardiac risk-stratification testing, 357
  cardiac stress testing, 344
  cardiac tamponade, 192, 280
  cardiac toxins. See drug-induced heart disease
  cardiac transplantation, 245
  cardiac troponins, 64
    troponin-I, 27, 147
    troponins T, 27
  cardiocerebral resuscitation, 131
    protocols, 134
  cardiogenic shock, 51, 55
    description of, 55
  cardiomyopathy, 258, 265
    background, 264
    case discussion, 258–63
    case presentation, 258
    case resolution, 263–4
    decision making, 265
    disposition of patients with, 265
    etiologies, 264
    history, 264
    physical examination, 264
    testing, 264–5
  cardiopulmonary resuscitation (CPR), 123, 124, 138
  cardiotoxicity, 252
  carotid-sinus syncope, 191
  catheterization, 340
    laboratory, 5, 40, 41
  Caucasian ethnicity, 26
  CCA-treated wood and in drug-induced heart disease, 248
  cell surface ADP-receptors, 28
  cellular phones, 154
  central venous pressure (CVP), 87
  cerebral hypoperfusion, 77
  CHADS2 scoring system, 93, 94
  chelation therapy, 248
  chemotherapeutic agents, 233
  chest pain, 3
    acute coronary syndrome (ACS), 7
    aortic dissection, 7–8
    aspirin affects of, 6
    background, 6–7
  cardiac tamponade, 9
  case presentation, 3–6
  CD4 count, 4
  chest X-ray study, 10–11
  decision making, 13
  diagnostic imaging studies, 11–12
  electrocardiogram (EKG), 10
  emergency department patients, disposition of, 13
  esophageal rupture, 9–10
  evaluation of, 3
  HIV history of patient, 4
  hypertension history of patient, 5
  initial chest pain workup, 7
  isometric exercise for, 4
  laboratory studies, 12–13
  patients with, testing for, 10
  pleuritic, 8
  pulmonary embolism, 8–9
  tension pneumothorax, 9
  chest radiography, 46, 82, 157
  chest X-ray, 148
    imaging, 12
    sensitivity, 11
    studies, 5, 9, 24, 129
  Chicago’s HeartSave Program, 144
  chronic obstructive pulmonary disease (COPD), 98,
    197, 289, 368
  chylous effusions, 234
  CK-MB, 234, 332
  class IA antidysrhythmic agents, in drug-induced heart
    disease, 252
  clevidipine, in the treatment of hypertensive emergency,
    305
  clonidine, for hypertensive emergency management, 304
  clopidogrel, 48
    benefits of, 28
  Clopidogrel and Metoprolol in Myocardial Infarction
    Trial (COMMIT), 28
  cocaine causing atrial dysrhythmias, 244
  colchicine, 234
  complete valvular dysfunction, 203
  computed tomography (CT)
    imaging, 11
    scan, 59
    tube voltage, 11
    venography, 13
  computed tomography angiogram (CTA), 5, 22,
    56, 57
    coronary angiogram, 353
  concomitant infectious process, 75
  concomitant symptomatology, 100
congenital coronary artery anomalies, 61
congenital heart disease, 202, 373
  in infants, 373
congenital heart lesion, 374
congestive heart failure (CHF), 192, 203, 305, 367
conventional angiography, 278
conventional coronary angiography
  resolution, 351
cooling method, 133
copper chromium arsenate, 248
coronary angiography, 43, 59, 60, 63
coronary arteries (CA), 356
  calcification, 352
dissection, clinical presentation in, 60
coronary artery disease (CAD), 22
  long-term predictors for, 25
  risk factors, 7
  risk factors for, 25
coronary care unit (CCU), 20, 75
coronary computed tomography, 349–58, 351
  cardiac computed tomography (CCT) angiography, 354–5
case discussion, 349–54
case presentation, 349
case resolution, 354
CCT use in ED populations, scientific basis for, 356–7
decision making, 358
  disadvantages, 351
  ideal diagnostic test, characteristics, 354
  image acquisition and interpretation, 355–6
  problem scope, 354
  unresolved issues regarding CCT in ED populations, 357–8
coronary spasm, 63
coronary vasospasm. See Prinzmetal’s angina
corticosteroid, 234
C-reactive protein (CRP) levels, 91
creatine kinase, 332
creatine kinase-MB fraction (CK-MB), 12
crescendo angina, 311
CURB-65 score, 13
current cardiopulmonary resuscitation (CPR)
  recommendations, 140
current leakage and inability, 154
Cushing’s syndrome, 79
cyclosporine, for hypertensive emergency management, 304
cytomegalovirus, 233
D-dimer, 276
  for acute aortic dissection, 277
  assay, 8
  testing, 13
deep venous thrombosis (DVT), 8, 189
  clinical signs/symptoms, 8
defibrillation, 125
dehiscence, 367
depolarization, 154
digitalis, in drug-induced heart disease, 250
  use of, 93
diltiazem, 93, 99
2,3-dimercaptopropanol-sulfonic acid, 248
direct thrombin inhibitors (DTI), 30
dobutamine, for acute valvular heart disease, 205
“door-to-balloon” (DTB) time, 46, 56
“door-to-needle” time, 47
dopamine, for acute valvular heart disease, 205
doxorubicin, 233
Dressler’s-like pericarditis, 369
Dressler’s syndrome, 52, 233, 366
drug-induced heart disease, 237
  anti-cancer chemotherapeutic agents, 252
  beta-adrenergic blockers, 250–1
  calcium channel blockers, 251–2
  case discussion, 237–41
  case presentation, 237
  case resolution, 241–2
chemotherapeutic cardiac toxins, 252
  class IA antidysrhythmic agents, 252
  decision making, 253
digitalis, 250
environmental toxins, 247
  antimony, 247–8
  arsenic, 248
  cobalt, 247
  lead, 247
  mercury, 247
  organic solvents, 248
  thallium, 248
medicinal toxins
  cardiac agents, 250
  medication-induced QT prolongation, 249–50
  phosphodiesterase 5 inhibitors, 248–9
recreational toxins, 242
  alcohol, 244–6
  amphetamine, 246–7
  cocaine, 242–4
drug-induced QT prolongation, 249
  dual-chamber pacemakers, 149
beta-agonist effect, 132
use of, 132
epistaxis, 247
epitifibatide
benefits of, 29
erthropoietin, for hypertensive emergency management, 304
esmolol, for hypertensive emergency management, 304
esophageal rupture
cause of, 9
European Resuscitation Council guidelines, 90
external defibrillation, 152
external pacing, 152
factor V Leiden, 8
FAST window, 129
subxiphoid ultrasound window, schematic presentation, 129
febrile illness, 154
fenoldopan, acts at peripheral D1 receptors, 304
fi brolytic agents, 47
fi brolytic therapy, 40, 41, 47, 51
absolute contraindications to, 47
EKG criteria for, 47
relative contraindications to, 47
fi brolytic-specific agent, 48
fi brolytic-specific fi brolytic therapy, 49
fibromuscular dysplasia, 303
first-degree atrioventricular block, 81
fluid drainage, 234
fluoroscopy, 149
Framingham study, 91
Frank-Starling curve, 204
Frank T-wave inversions, 6
Frog sign, 102
Glasgow Coma Scale (GCS), 62
glucagon, 84
glycoprotein (GP)
2b-3a receptors, 43
Ilb/Ilia inhibitors, 29, 30
inhibitor, 20
GRACE registry, 42
HACEK organisms, 203
Hamman’s crunch, 10
harsh systolic murmur, 51
heart failure
evidence of, 153
symptoms, 373
hemodynamic compromise, 152, 156
heparin-induced thrombocytopenia (HIT)
  history of, 49
hepatojugular reflux, 261
high dosages of epinephrine (HDE), 132
His-Purkinje system, 82, 118
HIV-related pericardial disease, 233
hydralazine, in the treatment of hypertensive emergency, 305
hyperglycemia, 23
hyperkalemia, 132, 154
  associated tachycardia, 120
  high risk for, 133
hyperlipidemia, 197
hypertension (HTN), 8, 86, 197, 280, 302
hypertensive emergencies, 297
  background, 302–3
  case discussion, 297–302
  case presentation, 297
  case resolution, 302
  decision making, 305
  defined, 303
  epidemiology, 302–3
  history, 303–4
hypertensive emergencies by organ system, 303
hypertrophy of cardiac muscles, 265
hypoglycemia, 374
hypokalemia, 149
hypokinesia, 64
hypomagnesemia, 245
hypotension, 8, 64, 232, 280
hypothyroidism, 154
hypovolemia, 191
hypoxemia, 154
hypoxia, 373

idiointerstitial rhythm, 79, 80
implantable cardioverter-defibrillators (ICDs), 151
  malfunction, 155
infarct-related artery (IRA), 44
infiltrative/inflammatory myocardial processes, 27
in-hospital cardiac arrest, 124
interventricular septum, 78
intraluminal thrombus, 289
intraterine pregnancy (IUP), 186
intravenous cocaine and endocarditis, 244
Intravenous drug abuse (IVDA), 202, 203
intravenous magnesium sulfate, 249
intubation, 203
ischemia, 154, 332
Ischemic coronary syndrome, 350
ischemic myocardium
  sympathetic stimulation of, 49
Ischiorectal abscess, 366
isoproterenol, 76
isoproteronol, 250
IV amiodarone
  use of, 93
IV beta-blocker therapy
  risks, 40
jugular venous distention (JVD), 304
jugular venous pressure (JVP), 9, 203
junctional ectopic tachycardia, 103
Korotkoff sound, 232
labatolol, for hypertensive emergency management, 304
lamifiban, 29
left anterior descending artery (LAD), 45, 60
left bundle branch block, 321–3
left ventricular assist device (LVAD), 367, 370
left ventricular hypertrophy (LVH), 186, 333
leishmaniasis, 247
levosimendan, 178
life-threatening pacemaker-mediated tachycardias, 156
lightheadedness, 153
hypothyroidism, 154
hypovolemia, 191
hypoxemia, 154
hypoxia, 373
magnetic resonance imaging, 12
major adverse cardiac events (MACE), 357
Marfan’s syndrome, 8, 203, 276, 280
MAST suit, 99
maximum intensity projection (MIP), 355
metabolic abnormalities, 149
metoprolol, 76
  therapy, 367
milrinone, 178
mitral regurgitation (MR), 51, 202
mitral valve prolapse, 202
low molecular weight heparins (LMWH), 29, 30, 49
malignant hypertension, 280
mass (intracardiac), 289
massive pulmonary embolism, 289
maximum intensity projection (MIP), 355
metabolic abnormalities, 149
metoprolol, 76
  therapy, 367
milrinone, 178
mitral regurgitation (MR), 51, 202
mitral valve prolapse, 202
intravenous cocaine and endocarditis, 244
intravenous drug abuse (IVDA), 202, 203
intravenous magnesium sulfate, 249
intubation, 203
ischemia, 154, 332
Ischemic coronary syndrome, 350
ischemic myocardium
  sympathetic stimulation of, 49
Ischiorectal abscess, 366
isoproterenol, 76
isoproteronol, 250
IV amiodarone
  use of, 93
IV beta-blocker therapy
  risks, 40
jugular venous distention (JVD), 304
jugular venous pressure (JVP), 9, 203
junctional ectopic tachycardia, 103
Korotkoff sound, 232
labatolol, for hypertensive emergency management, 304
lamifiban, 29
left anterior descending artery (LAD), 45, 60
left bundle branch block, 321–3
left ventricular assist device (LVAD), 367, 370
left ventricular hypertrophy (LVH), 186, 333
leishmaniasis, 247
levosimendan, 178
life-threatening pacemaker-mediated tachycardias, 156
lightheadedness, 153
hypothyroidism, 154
hypovolemia, 191
hypoxemia, 154
hypoxia, 373
magnetic resonance imaging, 12
major adverse cardiac events (MACE), 357
Marfan’s syndrome, 8, 203, 276, 280
MAST suit, 99
maximum intensity projection (MIP), 355
metabolic abnormalities, 149
metoprolol, 76
  therapy, 367
milrinone, 178
mitral regurgitation (MR), 51, 202
mitral valve prolapse, 202
intravenous cocaine and endocarditis, 244
intravenous drug abuse (IVDA), 202, 203
intravenous magnesium sulfate, 249
intubation, 203
ischemia, 154, 332
Ischemic coronary syndrome, 350
ischemic myocardium
  sympathetic stimulation of, 49
Ischiorectal abscess, 366
isoproterenol, 76
isoproteronol, 250
IV amiodarone
  use of, 93
IV beta-blocker therapy
  risks, 40
jugular venous distention (JVD), 304
jugular venous pressure (JVP), 9, 203
junctional ectopic tachycardia, 103
Korotkoff sound, 232
labatolol, for hypertensive emergency management, 304
lamifiban, 29
left anterior descending artery (LAD), 45, 60
left bundle branch block, 321–3
left ventricular assist device (LVAD), 367, 370
left ventricular hypertrophy (LVH), 186, 333
leishmaniasis, 247
levosimendan, 178
life-threatening pacemaker-mediated tachycardias, 156
lightheadedness, 153
hypothyroidism, 154
hypovolemia, 191
hypoxemia, 154
hypoxia, 373
magnetic resonance imaging, 12
major adverse cardiac events (MACE), 357
Marfan’s syndrome, 8, 203, 276, 280
MAST suit, 99
maximum intensity projection (MIP), 355
metabolic abnormalities, 149
metoprolol, 76
  therapy, 367
milrinone, 178
mitral regurgitation (MR), 51, 202
mitral valve prolapse, 202
Mobitz type 1 block, 81
Mobitz type 2 block, 81
Mobitz type 2 (2:1) block, 82
monomorphic ventricular tachycardia, 114
morphine sulfate, 49
multidetector CT (MDCT) scanner, 355
coronary angiography, 279
multifocal atrial tachycardia (MAT), 109
multi-planar reformations (MPR), 355
*Mycobacterium tuberculosis*, 231, 233
myocardial infarctions (MIs), 5, 21, 59, 91, 226, 369
acute, 38
chemical diagnosis of, 332–5
clinical classification, 333
clinical classification of, 26
diagnosis of, 64
pain treatment of, 41
rule-out, 12
myocardial ischemia, 190
aortic dissection with coronary occlusion, 61
carbon monoxide poisoning, 61–2
case discussion, 54–9
case presentation, 54
case resolution, 59
genetic coronary artery anomalies, 61
coronary artery dissection, 60–1
coronary embolism, 59–60
coronary vasoospasm, 62–3
decision making, 65
Takotsubo cardiomyopathy, 63–5
thyrotoxicosis, 63
unusual causes of, 54–65
myocardial perfusion testing, 345
myocardial rupture, 51
myocarditis
background, 213
case discussion, 209–13
case presentation, 209
causative agents, 215
decision making, 223
disposition of patients with, 222
epidemiology, 214
etiologies of, 214
high dose gamma globulin (IVIG) therapy, 221
history and physical examination, 216
pathophysiology, 215–16
prognosis, 221–2
special presentations, 216
specific therapies
  in certain populations, 221
testing, 216–20
treatment, 220–1
myoglobin, 333
myopericarditis, 230
native cardiac depolarizations, 153
nausea, 191
neoplastic-related pericarditis, 233
neurally-mediated hypotension, 191
neurological syncope, 191
nitroglycerin, 27, 62, 243
coadministration, 59
intravenous infusion, 49
nitroprusside
for acute valvular heart disease, 205
therapy in hypertensive emergencies, 305
nodal blocking agents, 79
nonatherosclerotic
cause of cardiac ischemia, 59
noncardiogenic pulmonary edema, 247
nonsteroidal antinflammatory agents (NSAIDs), 229, 234
non-ST segment elevation myocardial infarction (NSTEMI), 10, 18–30, 25, 311, 334
background, 19–30
case discussion, 18–24
case presentation, 18
decision making, 30
North American Society of Pacing and Electrophysiology (NASPE), 152
NPD code
for ICDs, 157
NPG code, 152
for pacemakers, 157
nursing home records, 147
Ontario Prehospital Advanced Life Support (OPALS), 130, 141
study group, 126
OOHCA survivors, 131
out-of-hospital cardiac arrest strategies, 138–58
barriers to early therapy, 144–5
case discussion, 138–40
case presentation, 138
case resolution, 140
decision making, 145
EMS timely response, challenge, 142
public access defibrillation, 142–3
public access defibrillation programs, 143–4
sudden cardiac arrest
importance of early therapy, 141–2
pacificer-mediated tachycardias (PMTs), 154
pacemakers, 75
and ICDs, 152
malfunction, 153, 154, 157
patients with dysfunction, 152
background, 151–2
case discussion, 147–51
case presentation, 147
decision making, 157–8
differential diagnosis, 153–5
disposition, 156–7
etiologies, 153–5
history and physical examination, 152–3
testing, 155–6
syndrome, 155
wires, 366
pacemaker-sensing threshold, 154
pain
chest (See chest pain)
“ripping”/“tearing,” 7
palpitations, 191
of the chest, 203
panic disorders, 192
paroxysmal atrial tachycardia (PAT), 110
pediatric cardiac emergencies, 372–80
atrial fibrillation, rate control medications for, 380
case discussion, 372–6
case resolution, 376–7
concepts of
background/epidemiology, 377
disposition, 378–9
etiologies/differential diagnosis, 378
initial workup, 377
management, 378
testing, 378
decision making, 379–80
percutaneous coronary interventions (PCIs), 10, 21, 39, 46, 134, 312
availability of, 41
pericardial effusion, 369
pericardiocentesis, 234, 280
pericarditis
acute vs. coronary syndromes, 235
background, 230–1
case discussion, 226–30
case presentation, 226
causes of acute pericarditis, 231
decision making, 235
differential diagnosis, 232–3
disposition, 234–5
epidemiology, 230–1
etiologies, 232–3
hospitalization for patients, indications for
with acute pericarditis, 235
initial workup history, 231–2
physical examination, 231–2
testing, 233–4
perimyocarditis, 230
peripheral edema, 261
pharmacologic stress testing, 345
phosphodiesterase inhibitors (PDEIs), 177–8
phosphodiesterase 5 inhibitors, in drug-induced heart
disease, 248
physical examination, 153
findings of alcoholic cardiomyopathy, 244
of STEMI patient, 227
PIOPED II investigators, 13
platelet inhibitors, 48
polyarteritis nodosa, 303
PORT score/pneumonia severity index, 13
postarrest/therapeutic hypothermia (TH) induction
protocol for, 134
post-CABG chest radiograph, 369
postcardiac surgery emergencies, 363–71
background and epidemiology, 367–8
case discussion, 364–7
case presentation, 363–4
case resolution, 367
decision making, 371
dysrhythmias, 368–9
infections, 369
left ventricular assist devices, 370
myocardial infarction, 369
neurological complications, 368
pericardial effusion, 369
valvular surgery, 370–1
postop cardiac patients
fever, causes of, 369
postoperative myocardial infarction (MI), 365
postpericardiotomy syndrome, 233
preexcitation syndrome, 106
premature atrial contractions (PACs), 73
premature ventricular contraction (PVC), 73
pre-syncope, 153
Prinzmetal's angina, 62, 63
propranolol, for hypertensive emergency management, 304
propylthiouracil (PTU), 89

391
INDEX

protein synthesis, 245
PR-segment depression, 234
psychiatric disorders, 192
public access defibrillation (PAD) approach, 139
initiative, 141
programs, 143–4
strategy, 142–3
pulmonary edema, 203
pulmonary embolism (PE), 5, 8, 10, 57, 87
poor specificity for, 8
symptoms of, 8
pulmonary embolism rule-out criteria (PERC) rule, 8, 9
pulmonary embolus (PE), 188
pulse rate, 147
P wave, 149, 155

QRS complexes, 78, 79, 82, 97, 98, 103, 104, 110, 112, 116, 119, 121, 149, 151, 155, 245, 252, 321, 322
QRS voltage, 51
QT syndrome, 250

radiation therapy, 233
rapid imaging, 9
rapid sequence intubation (RSI), 374
rapid sinus tachycardia, 102
regular, narrow QRS complex tachycardia
initial 12-lead EKG demonstrating, 98
respiratory distress, 203
respiratory management drugs, 76
respiratory syncytial virus (RSV), 373
resuscitation, 156
resveratrol decreases arterial damage, 246
retavase plasminogen activator (r-PA), 48
return of spontaneous circulation (ROSC), 128, 132
revascularization treatment, 48
revised Geneva score (RGS), 8
rheumatic heart disease, 203
rheumatologic diseases, 78
right coronary artery (RCA), 45, 60
right ventricular (RV)
infarction, 45, 51
paced rhythm, 323
risk-stratification scores, 357
Roth spots, 202

salvage angioplasty, 41
scanning techniques, 11
schistosomiasis, 247

sensor-induced tachycardias, 154
serial cardiac biomarkers, 112
serial cardiac enzymes, 76
serologic test's markers of acute inflammation, 234
serum electrolytes, 157
“shockable rhythm” concept, 141
sick sinus syndrome, 78
sildenafil, 248
sino-atrial (SA) node, 77
sinus bradycardia, 79
sinus tachycardia (ST), 109, 115
Sjogren's syndrome, 78
skeletal muscle fasciculations, 153
skeletal muscle myopotentials, 153
sodium channel blocker, 133
toxicity, 252
solvent abuse, 248
somatization disorder, 192
standard antipotassium pharmacologic therapy, 125
standard dosages of epinephrine (SDE), 132
Stanford type A aortic dissection, 61
Staphylococcus aureus, 204
infections, 202
ST-elevation myocardial infarction (STEMI), 25, 124
EKG evidence, 127
steroids, 229
streptokinase, 41, 322
use of, 42
stress, 337
background, 343
case discussion, 338–43
case presentation, 337–8
case resolution, 343
decision making, 347
differential diagnosis, 343–4
disposition, 345–6
etiology, 343–4
management, 346
test, 4, 5, 21, 23, 98, 353
testing, 344–5
stroke-like syndromes, 8
ST-segment depression, 40
ST-segment deviation, 92
ST-segment elevation, 62, 151, 234
in ischemia, 233
ST-segment elevation myocardial infarction (STEMI), 10, 138, 227, 300, 334
case discussion, 38–43
case presentation, 38
case resolution, 42–3

392
clinical criteria for, 43
clinical presentation in, 43–4
complication of, 51
complications of, 44, 49–52
decision making of, 52
emergency department diagnosis, 44–6
epidemiology and pathophysiology, 43
pathophysiology of, 43
pharmacological therapy for, 48
prognosis of, 49
reperfusion era, 43
treatment of, 46–9, 57
ST/T ratio, 234
subcutaneous emphysema, 10
sucinylcholine, 76
sudden cardiac arrest (SCA), 140
majority, 140
sudden death, 190
supraventricular tachycardia, 97–107
background/epidemiology, 101–2
case discussion, 97–101
case presentation, 97
case resolution, 101
decision making, 106–7
etiologies, 102–3
initial workup history and physical examination, 102
testing, 103–5
treatment and disposition, 105–6
supraventricular tachycardia (SVT), 98, 112, 115
definition, 101
emergency department interventions for patients, 107
forms, 103
“lone” paroxysmal, 101
oxygen saturation, 373
syncope, 102, 153
background, 189–90
case discussion, 185–9
case presentation, 185
case resolution, 189
decision making, 194
disposition of patients with, 194
Boston syncope guidelines, 194
risk factors and disposition, 193
San Francisco syncope rule, 194
in elderly patients, 192
etiologies of, 191–2
history and physical examination, 190–1
management, 194
testing in, 192–4
vs. seizure, 190
systemic lupus erythematosus, 233
systemic vascular resistance, 178
tachycardia, 73, 98, 108, 150, 232
tachydysrhythmias, 50
differential diagnosis for, 106
TACTICS trial, 20
tadalafil, 248
Takotsubo cardiomyopathy (TC), 27, 58, 63–5.
See also apical ballooning syndrome
diagnosis of, 59
EKG in, 64
management of, 65
Mayo Clinic criteria for, 64
telemetry, 157
tenecteplase (TNK), 48
tension pneumothorax, 9
termination of resuscitation (TOR), 134
rules, 134
therapeutic hypothermia (TH), 133
thiamine deficiency, 245
third-degree atrioventricular block, 83
thyrotoxicosis, 63, 261
time-tested interventions, 128
TIMI risk scores, 29, 352, 357
tissue plasminogen activator (t-PA), 48, 322
Torsades de pointes, 249
transesophageal echocardiogram (TEE), 12, 92, 94,
204, 278
transient global amnesia, 191
transient ischemic attack (TIA), 54
trans-thoracic echocardiography (TTE), 9, 204,
234, 276
traumatic coronary artery dissection, 60
treadmill, 337
triage vital signs, 147
tricyclic antidepressant (TCA) drugs, 112, 133
triglycerides, 234
troponins, 92, 234, 333, 334
troponin I testing, 12
troponin T
role, 12
T wave, 155
inversions, 151
UA/NSTEMI
aspirin administration for, 28
bleeding for, 30
management, 28
therapy for, 27
TIMI risk score for, 29
UK National Institute for Health and Clinical Excellence, 90
ultrasound, 74
probe, 74
unfractionated heparin (UFH), 47, 48, 49
dose of, 49
inhibits factor Xa, 29
route of administration, 29
therapy, 29
unstable angina (UA), 25, 311
uremia, 233
vagal maneuvers, 99, 105
valsalva maneuver, 99
valvular abnormality, 202
valvular heart disease
background, 202
case discussion, 197–201
case presentation, 197
case resolution, 201–2
decision making, 208
differential diagnosis, 203–4
disposition of patients with valvular disease, 208
etiologies, 203–4
history and physical examination, 202
acute valvular regurgitation, 203
flowchart for, 206
endocarditis, 202–3
Duke criteria for diagnosing, 205
management, flowchart for, 207
testing in, 204
treatment of patients with, 205–8
vardenafil, 248
vasopressors, 132
vasospasm, 63
vasovagal syncope, 191, 192
ventilation-perfusion scans, 12
ventricular dysrhythmia, 192
ventricular escape rhythm, 79. See also idioventricular rhythm
ventricular fibrillation (VF), 51, 124
arrest, 141
ventricular pacing, 147
ventricular septal defect (VSD), 51
ventricular tachycardia (VT), 22, 51, 108–22, 113, 117, 118, 124, 151, 192
viral-induced effusions, 232
volume-rendered techniques (VRT), 355
VQ scan, 188–9
VVI pacemakers, 151, 153, 155
weakness, 153
Wegener’s granulomatosis, 78
Wellens’ sign. See Wellens’ syndrome
Wellens’ syndrome, 10
Well's score, 8
wide complex tachycardia (WCT)
case discussion, 108–12
case presentation, 108
case resolution, 112
clinical presentation in, 115–20
decision making, 121–2
differential diagnosis, 108–22
disposition of patients with, 208
hemodynamically-stable, 122
management, 120–1
wide QRS complex tachycardia
electrocardiographic rhythm, 113
Wolfe-Parkinson-White syndrome (WPW), 90, 100, 105, 110, 119, 121, 132
rhythm disturbance, 112
in wide QRS complex tachycardia, 120
X-ray source, 355
X-ray studies, 12